| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 75 | 2024 | 1037 | 7.200 |
Why?
|
| Cancer Survivors | 7 | 2024 | 89 | 3.180 |
Why?
|
| Colorectal Neoplasms | 9 | 2020 | 656 | 2.810 |
Why?
|
| Postmenopause | 24 | 2020 | 267 | 2.790 |
Why?
|
| Genetic Predisposition to Disease | 45 | 2023 | 414 | 2.380 |
Why?
|
| Prostatic Neoplasms | 26 | 2016 | 298 | 2.020 |
Why?
|
| Polymorphism, Single Nucleotide | 39 | 2020 | 412 | 1.870 |
Why?
|
| Humans | 147 | 2024 | 18430 | 1.840 |
Why?
|
| Female | 115 | 2024 | 13136 | 1.790 |
Why?
|
| Aged | 78 | 2024 | 6417 | 1.760 |
Why?
|
| Middle Aged | 81 | 2024 | 8284 | 1.710 |
Why?
|
| Polymorphism, Genetic | 16 | 2009 | 78 | 1.620 |
Why?
|
| Neoplasms | 11 | 2022 | 457 | 1.540 |
Why?
|
| Risk Factors | 55 | 2024 | 3449 | 1.300 |
Why?
|
| Estrogens | 10 | 2018 | 73 | 1.250 |
Why?
|
| Feces | 4 | 2018 | 88 | 1.190 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 11 | 2005 | 16 | 1.160 |
Why?
|
| Microbiota | 3 | 2015 | 7 | 1.100 |
Why?
|
| Sequence Analysis, DNA | 4 | 2018 | 38 | 1.080 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2021 | 57 | 1.070 |
Why?
|
| Quality Improvement | 4 | 2023 | 207 | 1.030 |
Why?
|
| Cohort Studies | 41 | 2022 | 2672 | 1.030 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 177 | 1.020 |
Why?
|
| ras Proteins | 3 | 2014 | 24 | 0.990 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2014 | 36 | 0.990 |
Why?
|
| Carcinoma | 4 | 2012 | 27 | 0.970 |
Why?
|
| Genetic Testing | 11 | 2023 | 89 | 0.970 |
Why?
|
| Male | 58 | 2022 | 10440 | 0.960 |
Why?
|
| Adult | 45 | 2024 | 7910 | 0.940 |
Why?
|
| Mastectomy, Simple | 2 | 2013 | 3 | 0.900 |
Why?
|
| Aged, 80 and over | 27 | 2024 | 2003 | 0.860 |
Why?
|
| Case-Control Studies | 31 | 2017 | 1173 | 0.850 |
Why?
|
| Genotype | 26 | 2016 | 253 | 0.840 |
Why?
|
| Gonadal Steroid Hormones | 7 | 2010 | 33 | 0.810 |
Why?
|
| Biological Specimen Banks | 1 | 2022 | 13 | 0.800 |
Why?
|
| United States | 34 | 2024 | 4164 | 0.780 |
Why?
|
| Medical Marijuana | 1 | 2020 | 24 | 0.700 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 249 | 0.680 |
Why?
|
| Hormone Replacement Therapy | 6 | 2016 | 28 | 0.680 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2018 | 6 | 0.670 |
Why?
|
| Surveys and Questionnaires | 13 | 2020 | 1389 | 0.660 |
Why?
|
| Melanoma | 1 | 2019 | 37 | 0.650 |
Why?
|
| Quality of Life | 2 | 2020 | 529 | 0.650 |
Why?
|
| Germ-Line Mutation | 5 | 2022 | 23 | 0.640 |
Why?
|
| Cost of Illness | 1 | 2019 | 100 | 0.640 |
Why?
|
| Retrospective Studies | 18 | 2024 | 2550 | 0.630 |
Why?
|
| Genetic Variation | 9 | 2010 | 87 | 0.630 |
Why?
|
| Bariatric Surgery | 2 | 2020 | 130 | 0.630 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 64 | 0.620 |
Why?
|
| Immunoglobulin A | 1 | 2018 | 4 | 0.620 |
Why?
|
| Bacteria | 1 | 2018 | 6 | 0.620 |
Why?
|
| Obesity | 5 | 2017 | 855 | 0.600 |
Why?
|
| Mutation | 4 | 2014 | 132 | 0.590 |
Why?
|
| Registries | 6 | 2022 | 490 | 0.580 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2010 | 17 | 0.560 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 54 | 0.560 |
Why?
|
| Delivery of Health Care, Integrated | 6 | 2023 | 567 | 0.550 |
Why?
|
| Incidence | 21 | 2024 | 1314 | 0.550 |
Why?
|
| Prognosis | 10 | 2022 | 624 | 0.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 50 | 0.530 |
Why?
|
| Genome, Human | 7 | 2011 | 42 | 0.530 |
Why?
|
| Premenopause | 3 | 2020 | 27 | 0.530 |
Why?
|
| Young Adult | 8 | 2024 | 2518 | 0.520 |
Why?
|
| Specimen Handling | 2 | 2014 | 22 | 0.510 |
Why?
|
| Genomics | 3 | 2014 | 66 | 0.510 |
Why?
|
| Genetic Loci | 5 | 2014 | 60 | 0.510 |
Why?
|
| Mouth Mucosa | 3 | 2007 | 5 | 0.500 |
Why?
|
| Alleles | 11 | 2014 | 95 | 0.500 |
Why?
|
| DNA | 3 | 2007 | 25 | 0.500 |
Why?
|
| Prospective Studies | 22 | 2011 | 1314 | 0.490 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 7 | 0.470 |
Why?
|
| Electronic Health Records | 6 | 2022 | 747 | 0.460 |
Why?
|
| Weight Gain | 2 | 2006 | 181 | 0.440 |
Why?
|
| Neoplasm Staging | 8 | 2019 | 337 | 0.440 |
Why?
|
| Genome-Wide Association Study | 10 | 2020 | 252 | 0.440 |
Why?
|
| Weight Loss | 2 | 2017 | 321 | 0.430 |
Why?
|
| DNA Mutational Analysis | 2 | 2012 | 21 | 0.430 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2024 | 43 | 0.430 |
Why?
|
| Neoplasms, Second Primary | 2 | 2023 | 31 | 0.420 |
Why?
|
| Receptors, Estrogen | 7 | 2024 | 58 | 0.420 |
Why?
|
| Odds Ratio | 11 | 2015 | 701 | 0.420 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 11 | 0.410 |
Why?
|
| Follow-Up Studies | 13 | 2020 | 1269 | 0.390 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 3 | 2006 | 6 | 0.380 |
Why?
|
| Endometrial Neoplasms | 4 | 2008 | 39 | 0.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2014 | 55 | 0.370 |
Why?
|
| Age Factors | 7 | 2019 | 965 | 0.370 |
Why?
|
| Adolescent | 6 | 2022 | 3798 | 0.360 |
Why?
|
| Tamoxifen | 4 | 2024 | 60 | 0.360 |
Why?
|
| European Continental Ancestry Group | 13 | 2011 | 554 | 0.360 |
Why?
|
| Haplotypes | 9 | 2011 | 43 | 0.350 |
Why?
|
| Peripheral Vascular Diseases | 3 | 1995 | 7 | 0.350 |
Why?
|
| Receptors, Adiponectin | 1 | 2009 | 1 | 0.350 |
Why?
|
| Receptors, Leptin | 1 | 2009 | 3 | 0.350 |
Why?
|
| Risk Assessment | 12 | 2015 | 1143 | 0.350 |
Why?
|
| Anthracyclines | 2 | 2024 | 16 | 0.350 |
Why?
|
| Leptin | 1 | 2009 | 30 | 0.340 |
Why?
|
| Age of Onset | 2 | 2019 | 82 | 0.330 |
Why?
|
| Risk | 15 | 2017 | 552 | 0.330 |
Why?
|
| Chromosome Mapping | 6 | 2011 | 23 | 0.330 |
Why?
|
| Hormones | 3 | 2022 | 17 | 0.320 |
Why?
|
| Insurance, Health | 2 | 2022 | 217 | 0.320 |
Why?
|
| Aromatase Inhibitors | 3 | 2024 | 35 | 0.320 |
Why?
|
| Receptors, Adrenergic, beta-3 | 1 | 2008 | 1 | 0.320 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2008 | 3 | 0.320 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2008 | 5 | 0.320 |
Why?
|
| Pilot Projects | 5 | 2015 | 237 | 0.320 |
Why?
|
| Ghrelin | 1 | 2008 | 15 | 0.320 |
Why?
|
| Overweight | 1 | 2011 | 276 | 0.320 |
Why?
|
| Body Mass Index | 6 | 2010 | 974 | 0.320 |
Why?
|
| Databases, Factual | 6 | 2017 | 327 | 0.310 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 365 | 0.310 |
Why?
|
| American Cancer Society | 4 | 2004 | 16 | 0.300 |
Why?
|
| Data Collection | 4 | 2019 | 275 | 0.300 |
Why?
|
| Carcinoma, Lobular | 2 | 2009 | 12 | 0.300 |
Why?
|
| Trastuzumab | 3 | 2024 | 17 | 0.300 |
Why?
|
| Receptors, Progesterone | 2 | 2022 | 52 | 0.290 |
Why?
|
| Outcome Assessment (Health Care) | 3 | 2014 | 254 | 0.290 |
Why?
|
| Genetic Markers | 3 | 2009 | 28 | 0.290 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2024 | 65 | 0.280 |
Why?
|
| Carcinoma, Ductal | 1 | 2006 | 5 | 0.280 |
Why?
|
| Activin Receptors, Type I | 1 | 2006 | 1 | 0.280 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2006 | 3 | 0.280 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 9 | 0.280 |
Why?
|
| Colorado | 2 | 2019 | 211 | 0.270 |
Why?
|
| Logistic Models | 7 | 2015 | 962 | 0.270 |
Why?
|
| Reproducibility of Results | 6 | 2013 | 399 | 0.270 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 2014 | 6 | 0.270 |
Why?
|
| Neoplasm Proteins | 3 | 2014 | 12 | 0.260 |
Why?
|
| Proportional Hazards Models | 8 | 2019 | 743 | 0.250 |
Why?
|
| Multivariate Analysis | 6 | 2013 | 598 | 0.250 |
Why?
|
| Linkage Disequilibrium | 9 | 2011 | 39 | 0.250 |
Why?
|
| Hypertension | 2 | 2022 | 524 | 0.250 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2014 | 25 | 0.250 |
Why?
|
| Survival Rate | 4 | 2020 | 269 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2009 | 9 | 0.230 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2023 | 7 | 0.230 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2009 | 104 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 14 | 0.230 |
Why?
|
| Antineoplastic Agents | 3 | 2012 | 65 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 208 | 0.230 |
Why?
|
| Phenotype | 1 | 2014 | 148 | 0.230 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 3 | 0.220 |
Why?
|
| Telomerase | 2 | 2014 | 6 | 0.220 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 146 | 0.220 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2013 | 16 | 0.220 |
Why?
|
| Solvents | 1 | 2003 | 2 | 0.220 |
Why?
|
| Methionine | 1 | 2003 | 6 | 0.220 |
Why?
|
| Radiation Dosage | 2 | 2013 | 14 | 0.220 |
Why?
|
| Health Services Research | 2 | 2016 | 264 | 0.220 |
Why?
|
| Folic Acid | 1 | 2003 | 35 | 0.220 |
Why?
|
| Membrane Proteins | 2 | 2014 | 40 | 0.220 |
Why?
|
| Ethanol | 1 | 2003 | 23 | 0.210 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 2 | 0.210 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 2 | 0.210 |
Why?
|
| Sarcoma | 1 | 2022 | 3 | 0.210 |
Why?
|
| Adenoma | 1 | 2014 | 100 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2012 | 26 | 0.210 |
Why?
|
| Age Distribution | 4 | 2013 | 261 | 0.210 |
Why?
|
| Mortality | 3 | 2019 | 123 | 0.210 |
Why?
|
| Family | 2 | 2022 | 120 | 0.210 |
Why?
|
| Aromatase | 3 | 2009 | 10 | 0.200 |
Why?
|
| Menarche | 2 | 2005 | 30 | 0.200 |
Why?
|
| Patient-Centered Care | 2 | 2015 | 228 | 0.200 |
Why?
|
| Receptors, Androgen | 4 | 2010 | 13 | 0.200 |
Why?
|
| Menstrual Cycle | 3 | 2010 | 8 | 0.200 |
Why?
|
| Alcohol Drinking | 2 | 2003 | 375 | 0.200 |
Why?
|
| MicroRNAs | 1 | 2021 | 17 | 0.200 |
Why?
|
| Quality Control | 2 | 2012 | 48 | 0.190 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 3 | 2010 | 11 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2016 | 73 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2011 | 2 | 0.180 |
Why?
|
| Dog Diseases | 1 | 2020 | 1 | 0.180 |
Why?
|
| Mast Cells | 1 | 2020 | 1 | 0.180 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2020 | 2 | 0.180 |
Why?
|
| Hypothyroidism | 1 | 2020 | 8 | 0.180 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2000 | 9 | 0.180 |
Why?
|
| Kallikreins | 2 | 2011 | 5 | 0.180 |
Why?
|
| SEER Program | 2 | 2019 | 101 | 0.180 |
Why?
|
| Progesterone | 2 | 2009 | 7 | 0.180 |
Why?
|
| Delivery of Health Care | 4 | 2019 | 444 | 0.170 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 630 | 0.170 |
Why?
|
| Neoplasm Metastasis | 2 | 2014 | 33 | 0.170 |
Why?
|
| Hispanic Americans | 2 | 2002 | 428 | 0.170 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 2 | 2010 | 4 | 0.170 |
Why?
|
| Disease Susceptibility | 5 | 2016 | 46 | 0.160 |
Why?
|
| Quantitative Trait Loci | 2 | 2009 | 38 | 0.160 |
Why?
|
| Fertility | 2 | 2010 | 10 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2019 | 327 | 0.160 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1360 | 0.160 |
Why?
|
| Receptor, ErbB-2 | 2 | 2022 | 48 | 0.160 |
Why?
|
| Prostaglandins E, Synthetic | 1 | 2018 | 1 | 0.150 |
Why?
|
| DNA, Ribosomal | 1 | 2018 | 3 | 0.150 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 6 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 3 | 0.150 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 11 | 0.150 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 9 | 0.150 |
Why?
|
| Estradiol | 1 | 1998 | 24 | 0.150 |
Why?
|
| Qualitative Research | 1 | 2019 | 272 | 0.150 |
Why?
|
| Lymphoma | 1 | 2017 | 7 | 0.150 |
Why?
|
| Estrogen Receptor beta | 2 | 2008 | 12 | 0.150 |
Why?
|
| Rural Population | 1 | 1998 | 52 | 0.150 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2016 | 19 | 0.150 |
Why?
|
| DNA-Binding Proteins | 2 | 2009 | 31 | 0.150 |
Why?
|
| Motor Activity | 2 | 2010 | 215 | 0.150 |
Why?
|
| Cholesterol | 1 | 2017 | 112 | 0.150 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 11 | 0.150 |
Why?
|
| Urban Population | 1 | 1998 | 124 | 0.150 |
Why?
|
| Sex Factors | 1 | 2019 | 661 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2019 | 251 | 0.140 |
Why?
|
| Calcium Channel Blockers | 1 | 2017 | 15 | 0.140 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 526 | 0.140 |
Why?
|
| Family Health | 2 | 2013 | 49 | 0.140 |
Why?
|
| Prenatal Care | 1 | 1998 | 134 | 0.140 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 90 | 0.130 |
Why?
|
| Gene Frequency | 5 | 2014 | 48 | 0.130 |
Why?
|
| Thyroid Neoplasms | 1 | 2015 | 12 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 4 | 2012 | 83 | 0.130 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1995 | 8 | 0.130 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 2 | 0.130 |
Why?
|
| Survivors | 1 | 2017 | 158 | 0.130 |
Why?
|
| Vitamin D | 2 | 2007 | 80 | 0.130 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2015 | 4 | 0.130 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 172 | 0.130 |
Why?
|
| Process Assessment (Health Care) | 1 | 2015 | 28 | 0.130 |
Why?
|
| Social Class | 1 | 2015 | 125 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1996 | 61 | 0.120 |
Why?
|
| Epidemiologic Studies | 2 | 2007 | 32 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 182 | 0.120 |
Why?
|
| Linear Models | 1 | 2015 | 243 | 0.120 |
Why?
|
| Databases, Genetic | 1 | 2014 | 10 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2014 | 4 | 0.120 |
Why?
|
| Models, Genetic | 4 | 2011 | 24 | 0.120 |
Why?
|
| Computer Communication Networks | 1 | 2014 | 18 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 53 | 0.120 |
Why?
|
| Community Networks | 1 | 2014 | 28 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 259 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 150 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2016 | 1296 | 0.110 |
Why?
|
| Animals | 3 | 2020 | 261 | 0.110 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2013 | 4 | 0.110 |
Why?
|
| Ethnic Groups | 5 | 2010 | 501 | 0.110 |
Why?
|
| Prostate-Specific Antigen | 2 | 2011 | 77 | 0.110 |
Why?
|
| Progestins | 2 | 2010 | 28 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 197 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2013 | 13 | 0.110 |
Why?
|
| Incidental Findings | 1 | 2013 | 30 | 0.110 |
Why?
|
| Coronary Disease | 2 | 1992 | 185 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 49 | 0.110 |
Why?
|
| Research Design | 2 | 2014 | 402 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2007 | 321 | 0.110 |
Why?
|
| ErbB Receptors | 1 | 2012 | 7 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 7 | 0.110 |
Why?
|
| Mastectomy | 2 | 2022 | 39 | 0.100 |
Why?
|
| Codon | 1 | 2012 | 1 | 0.100 |
Why?
|
| Paraffin Embedding | 1 | 2012 | 6 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 13 | 0.100 |
Why?
|
| Tissue Fixation | 1 | 2012 | 4 | 0.100 |
Why?
|
| Observer Variation | 1 | 2012 | 40 | 0.100 |
Why?
|
| Reoperation | 1 | 2012 | 30 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2015 | 120 | 0.100 |
Why?
|
| Mastectomy, Segmental | 1 | 2012 | 23 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 43 | 0.100 |
Why?
|
| Mass Screening | 1 | 2017 | 690 | 0.100 |
Why?
|
| Community Participation | 1 | 2012 | 33 | 0.100 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 77 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 105 | 0.100 |
Why?
|
| Physical Chromosome Mapping | 1 | 2011 | 2 | 0.100 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2011 | 3 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2011 | 1 | 0.100 |
Why?
|
| Steroids | 1 | 2010 | 15 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2009 | 3 | 0.090 |
Why?
|
| Nutrition Surveys | 1 | 2011 | 63 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 195 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 1 | 1991 | 35 | 0.090 |
Why?
|
| Decision Making | 1 | 2012 | 204 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 188 | 0.090 |
Why?
|
| Leisure Activities | 1 | 2010 | 33 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 5 | 0.090 |
Why?
|
| Health Maintenance Organizations | 1 | 2012 | 479 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 1 | 2009 | 7 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2009 | 26 | 0.090 |
Why?
|
| Managed Care Programs | 1 | 2012 | 347 | 0.090 |
Why?
|
| Receptors, LHRH | 1 | 2009 | 1 | 0.090 |
Why?
|
| Protein Precursors | 1 | 2009 | 5 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2009 | 11 | 0.090 |
Why?
|
| African Americans | 3 | 2011 | 490 | 0.090 |
Why?
|
| Adiponectin | 1 | 2009 | 22 | 0.080 |
Why?
|
| Prostatic Secretory Proteins | 1 | 2009 | 1 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2009 | 4 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 3 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2009 | 4 | 0.080 |
Why?
|
| Mammography | 2 | 2023 | 174 | 0.080 |
Why?
|
| Receptors, Calcitriol | 1 | 2009 | 13 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 350 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2010 | 185 | 0.080 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 1 | 2008 | 1 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 2 | 2013 | 35 | 0.080 |
Why?
|
| Genetic Association Studies | 3 | 2016 | 35 | 0.080 |
Why?
|
| Medical Records | 2 | 2013 | 106 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2008 | 60 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2017 | 226 | 0.080 |
Why?
|
| Cryopreservation | 1 | 2007 | 1 | 0.080 |
Why?
|
| Blood Preservation | 1 | 2007 | 2 | 0.080 |
Why?
|
| Lymphocyte Count | 1 | 2007 | 2 | 0.080 |
Why?
|
| Cell Survival | 1 | 2007 | 8 | 0.080 |
Why?
|
| Blood Specimen Collection | 1 | 2007 | 8 | 0.080 |
Why?
|
| Lymphocyte Activation | 1 | 2007 | 8 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2009 | 69 | 0.070 |
Why?
|
| One-Carbon Group Transferases | 1 | 2007 | 1 | 0.070 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2007 | 3 | 0.070 |
Why?
|
| Body Weight | 1 | 2008 | 223 | 0.070 |
Why?
|
| Heart Failure | 1 | 2012 | 398 | 0.070 |
Why?
|
| Diet | 2 | 2007 | 371 | 0.070 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 1997 | 10 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2006 | 4 | 0.070 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2006 | 4 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2006 | 4 | 0.070 |
Why?
|
| Penetrance | 1 | 2005 | 4 | 0.070 |
Why?
|
| Genes, Neoplasm | 1 | 2005 | 4 | 0.070 |
Why?
|
| Calcium, Dietary | 1 | 2005 | 28 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 2 | 2009 | 27 | 0.070 |
Why?
|
| Dairy Products | 1 | 2005 | 23 | 0.070 |
Why?
|
| Follicular Phase | 1 | 2005 | 2 | 0.060 |
Why?
|
| Abortion, Spontaneous | 1 | 2006 | 52 | 0.060 |
Why?
|
| Menstruation | 1 | 2005 | 8 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 333 | 0.060 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2014 | 1 | 0.060 |
Why?
|
| Genes, Modifier | 1 | 2014 | 3 | 0.060 |
Why?
|
| Aspirin | 1 | 2005 | 67 | 0.060 |
Why?
|
| DNA Glycosylases | 1 | 2014 | 6 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 68 | 0.060 |
Why?
|
| Asian Americans | 2 | 2002 | 182 | 0.060 |
Why?
|
| Genetic Counseling | 1 | 2023 | 35 | 0.060 |
Why?
|
| Cooperative Behavior | 2 | 2015 | 102 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2006 | 724 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2013 | 37 | 0.060 |
Why?
|
| Eating | 1 | 2003 | 38 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2003 | 66 | 0.050 |
Why?
|
| Pregnancy | 3 | 2010 | 1516 | 0.050 |
Why?
|
| Jews | 1 | 2002 | 1 | 0.050 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2002 | 17 | 0.050 |
Why?
|
| Mouthwashes | 1 | 2001 | 4 | 0.050 |
Why?
|
| Women's Health | 1 | 2003 | 207 | 0.050 |
Why?
|
| Patients | 1 | 2022 | 38 | 0.050 |
Why?
|
| Reference Values | 1 | 2001 | 93 | 0.050 |
Why?
|
| ROC Curve | 2 | 2012 | 83 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2001 | 21 | 0.050 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2020 | 1 | 0.050 |
Why?
|
| Chromosomes, Mammalian | 1 | 2020 | 2 | 0.050 |
Why?
|
| Receptors, Thyrotropin | 1 | 2020 | 2 | 0.050 |
Why?
|
| Time Factors | 2 | 2017 | 1136 | 0.050 |
Why?
|
| Dogs | 1 | 2020 | 18 | 0.050 |
Why?
|
| Ovary | 1 | 2000 | 4 | 0.050 |
Why?
|
| Estradiol Dehydrogenases | 1 | 2000 | 3 | 0.050 |
Why?
|
| Europe | 2 | 2010 | 44 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 1 | 2000 | 14 | 0.050 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2000 | 12 | 0.050 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2000 | 13 | 0.050 |
Why?
|
| Reproductive History | 1 | 2000 | 18 | 0.040 |
Why?
|
| Cholestenone 5 alpha-Reductase | 2 | 1998 | 2 | 0.040 |
Why?
|
| Oxidoreductases | 2 | 1998 | 3 | 0.040 |
Why?
|
| Forecasting | 1 | 2000 | 80 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 4 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 8 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 45 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2019 | 29 | 0.040 |
Why?
|
| Medical Record Linkage | 2 | 2014 | 44 | 0.040 |
Why?
|
| Research | 1 | 2019 | 73 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2011 | 319 | 0.040 |
Why?
|
| Androgens | 1 | 1998 | 13 | 0.040 |
Why?
|
| Exons | 2 | 2009 | 10 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 143 | 0.040 |
Why?
|
| Genes | 1 | 1998 | 2 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 1998 | 6 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2013 | 1478 | 0.040 |
Why?
|
| Transcription Factors | 1 | 1998 | 20 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 1998 | 10 | 0.040 |
Why?
|
| Life Style | 3 | 2005 | 342 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2012 | 253 | 0.040 |
Why?
|
| Introns | 1 | 1997 | 10 | 0.040 |
Why?
|
| Insurance Claim Review | 1 | 2017 | 70 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 1998 | 109 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 1996 | 11 | 0.040 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 1996 | 6 | 0.040 |
Why?
|
| Immunoglobulin E | 1 | 1996 | 5 | 0.030 |
Why?
|
| Hydroxysteroid Dehydrogenases | 1 | 1996 | 1 | 0.030 |
Why?
|
| Carcinogenicity Tests | 1 | 1996 | 3 | 0.030 |
Why?
|
| Michigan | 1 | 2015 | 26 | 0.030 |
Why?
|
| Child | 2 | 2013 | 2571 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 108 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 1995 | 4 | 0.030 |
Why?
|
| Menopause | 1 | 2016 | 72 | 0.030 |
Why?
|
| Blood Pressure | 2 | 1994 | 310 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 12 | 0.030 |
Why?
|
| Pharmacoepidemiology | 1 | 2015 | 22 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 22 | 0.030 |
Why?
|
| Bacteroides | 1 | 2014 | 2 | 0.030 |
Why?
|
| Clostridium | 1 | 2014 | 3 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1998 | 392 | 0.030 |
Why?
|
| Community-Institutional Relations | 1 | 2015 | 47 | 0.030 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 1994 | 1 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1994 | 2 | 0.030 |
Why?
|
| Tibia | 1 | 1994 | 2 | 0.030 |
Why?
|
| Leg | 1 | 1994 | 4 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 87 | 0.030 |
Why?
|
| Ultrasonography | 1 | 1994 | 36 | 0.030 |
Why?
|
| Computational Biology | 1 | 2014 | 28 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 26 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 911 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2015 | 127 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2014 | 42 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2014 | 57 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 1996 | 249 | 0.030 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2013 | 2 | 0.030 |
Why?
|
| Hyperlipoproteinemia Type IV | 1 | 1993 | 1 | 0.030 |
Why?
|
| Hypolipoproteinemias | 1 | 1993 | 1 | 0.030 |
Why?
|
| Hemochromatosis | 1 | 2013 | 9 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 24 | 0.030 |
Why?
|
| Exome | 1 | 2013 | 25 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 15 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 1993 | 80 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 8 | 0.030 |
Why?
|
| Triglycerides | 1 | 1993 | 87 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 46 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 100 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2012 | 167 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 91 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 131 | 0.030 |
Why?
|
| Health Planning | 1 | 2012 | 17 | 0.030 |
Why?
|
| Intermittent Claudication | 1 | 1992 | 2 | 0.030 |
Why?
|
| African Continental Ancestry Group | 2 | 2007 | 166 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2014 | 266 | 0.030 |
Why?
|
| HapMap Project | 1 | 2011 | 2 | 0.030 |
Why?
|
| Focus Groups | 1 | 2012 | 154 | 0.020 |
Why?
|
| California | 1 | 1998 | 2365 | 0.020 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2010 | 5 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 2010 | 2 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 241 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 342 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2010 | 48 | 0.020 |
Why?
|
| Trinucleotide Repeats | 1 | 2010 | 2 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 7 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2012 | 256 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 34 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 50 | 0.020 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2009 | 1 | 0.020 |
Why?
|
| Inflammation | 1 | 2009 | 63 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2009 | 1 | 0.020 |
Why?
|
| Genome | 1 | 2009 | 4 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 9 | 0.020 |
Why?
|
| Hospitalization | 1 | 2015 | 847 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2009 | 23 | 0.020 |
Why?
|
| Heterozygote | 1 | 2009 | 29 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 271 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 1245 | 0.020 |
Why?
|
| Interleukin-16 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2008 | 4 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2008 | 8 | 0.020 |
Why?
|
| Cadherins | 1 | 2008 | 6 | 0.020 |
Why?
|
| Reference Standards | 1 | 2007 | 17 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2007 | 7 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 20 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 18 | 0.020 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2007 | 1 | 0.020 |
Why?
|
| Taq Polymerase | 1 | 2007 | 1 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 468 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 3 | 0.020 |
Why?
|
| New Jersey | 1 | 2006 | 6 | 0.020 |
Why?
|
| New York | 1 | 2006 | 22 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2005 | 3 | 0.020 |
Why?
|
| Massachusetts | 1 | 2006 | 99 | 0.020 |
Why?
|
| Exercise | 1 | 2010 | 495 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2006 | 159 | 0.020 |
Why?
|
| Smoking | 1 | 2005 | 494 | 0.010 |
Why?
|
| Hawaii | 1 | 2002 | 45 | 0.010 |
Why?
|
| Blood | 1 | 2002 | 2 | 0.010 |
Why?
|
| Los Angeles | 1 | 2002 | 141 | 0.010 |
Why?
|
| Marriage | 1 | 2002 | 7 | 0.010 |
Why?
|
| Nutrition Assessment | 1 | 2002 | 27 | 0.010 |
Why?
|
| Epidemiologic Research Design | 1 | 2002 | 24 | 0.010 |
Why?
|
| Diet Surveys | 1 | 2002 | 58 | 0.010 |
Why?
|
| Anthropometry | 1 | 2002 | 67 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2002 | 79 | 0.010 |
Why?
|
| Biomarkers | 1 | 2002 | 308 | 0.010 |
Why?
|
| Continental Population Groups | 1 | 2002 | 315 | 0.010 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 1 | 1998 | 1 | 0.010 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1997 | 12 | 0.010 |
Why?
|
| Axilla | 1 | 1996 | 3 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 1996 | 21 | 0.010 |
Why?
|
| Sex Distribution | 1 | 1996 | 198 | 0.010 |
Why?
|
| Ultrasonics | 1 | 1992 | 1 | 0.010 |
Why?
|